Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539614 · ClinicalTrials.gov registry record · Phase 3
Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests
A Phase 3 study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT03539614: Active Phase 3 study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
NCT03539614 is a Phase 3 study of Post Traumatic Stress Disorder that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 87 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03539614, a Phase 3 study of Post Traumatic Stress Disorder, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. There are a variety of treatment options for PTSD, including psychotherapy (talk therapy) options, as well as medications, such as the drug prazosin. Each of the treatment options available is effective at significantly reducing the symptoms of PTSD in some, but not all, individuals with PTSD. However, investigators are not yet able to predict in advance who is likely to respond to which of the available treatments. Neither are the investigators able to explain what changes in the brain after exposure to a traumatic stressors, and why it results in persistent symptoms of PTSD for some people, but not for others. In this study, the investigators are testing two things: First, is testing whether two simple, easy tests of how an individual's blood pressure changes with standing and how an individual's eye reacts to a pulse of light may be able to predict whether that person is likely to respond to the medication prazosin for PTSD. Second, is testing whether those who have been exposed to a traumatic stress show differences in how their body regulates the response to the stress-signal noradrenaline.
Primary Outcome
The PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) is a self-reported rating scale where an individual rates the severity of each symptom of PTSD on a Likert scale. The ratings on individual items are summed to create a total score, which ranges from 0 to 80, with higher scores indicating more symptoms. The relationship between changes in participants' total PCL scores at different time points and prazosin exposure - and whether this relationship is
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Washington
- VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 3 |
What the registry record for NCT03539614 still lists
NCT03539614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03539614 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03539614 about?
NCT03539614 is a clinical study titled "Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests". Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. There are a variety of treatment options for PTSD, including psychotherapy (talk therapy) options, as well as medications, such as the drug prazosin. Each of the treatment options available is effective a...
What is the current status of trial NCT03539614?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2018-06-04. Estimated completion is 2026-06-01.
What conditions does trial NCT03539614 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT03539614?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT03539614?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539614 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03539614's enrollment target sits among peer trials
87 123rd of 262 higher than 137 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
RECRUITING · Phase 3
-
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
RECRUITING · Phase 3
-
MDMA-assisted Massed Prolonged Exposure for PTSD
RECRUITING · Phase 3
-
Repurposing Low-Dose Clonidine for PTSD in Veterans
RECRUITING · Phase 3
-
Frontline Clinician Psilocybin Study
COMPLETED · Phase 3
-
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI